Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
暂无分享,去创建一个
J Cuzick | L Ambroisine | W. Gerald | J. Cuzick | D. Berney | P. Scardino | V. Reuter | J. Clark | C. Cooper | G. Kovacs | G. Kovacs | C. Foster | G. Attard | L. Ambroisine | G. Fisher | P. Flohr | A. Fletcher | H. Møller | J. Bono | G. Attard | G Fisher | C S Foster | P Flohr | J Clark | C S Cooper | A Fletcher | W L Gerald | V Reuter | G Attard | G Kovacs | D Berney | H Moller | J S De Bono | P Scardino | C. Foster | Colin S. Cooper
[1] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[2] D. Fryback,et al. Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.
[3] Juni Palmgren,et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.
[4] S. Moss,et al. A UK‐based investigation of inter‐ and intra‐observer reproducibility of Gleason grading of prostatic biopsies , 2006, Histopathology.
[5] T. H. van der Kwast,et al. Detection rates of high‐grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer , 2006, International journal of cancer.
[6] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[7] J. Cuzick,et al. Long-term outcome among men with conservatively treated localised prostate cancer , 2006, British Journal of Cancer.
[8] S. Yao,et al. Understanding and appreciating overdiagnosis in the PSA era. , 2002, Journal of the National Cancer Institute.
[9] D. Bostwick,et al. Cellular and Molecular Pathology of Prostate Cancer Precursors , 2000, Scandinavian journal of urology and nephrology. Supplementum.
[10] J. Epstein,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.
[11] O. Kallioniemi,et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.
[12] D. Cox,et al. Analysis of Survival Data. , 1986 .
[13] L. Klotz,et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.
[14] A. Hanlon,et al. The Gleason score shift: score four and seven years ago. , 2003, International journal of radiation oncology, biology, physics.
[15] G. Chodak,et al. Natural history of early localized prostate cancer. , 2004, JAMA.
[16] Rosalind Eeles,et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome , 2004, Oncogene.
[17] Paul W Dickman,et al. Natural history of early, localized prostate cancer. , 2004, JAMA.
[18] H. Frierson,et al. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years , 2002, Cancer.
[19] A. Ashworth,et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.
[20] D. Bostwick,et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.
[21] I. Panagopoulos,et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .
[22] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[23] Bostwick Dg,et al. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. , 1999 .
[24] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[25] Adam S. Kibel,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007 .
[26] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[27] R. Thisted,et al. Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.
[28] A. Evans,et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.
[29] Arul M Chinnaiyan,et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.
[30] C. Foster,et al. Pathology of benign prostatic hyperplasia , 2000, The Prostate. Supplement.
[31] James A Hanley,et al. Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.
[32] Takaaki Sano,et al. A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States. , 2005, Archives of pathology & laboratory medicine.
[33] J. Adolfsson,et al. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. , 1998, Urology.
[34] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.